Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing

By Qiang Cheng, Tuo Wei, L. Farbiak, Lindsay T. Johnson, Sean A. Dilliard, D. Siegwart. Nature Nanotechnology, 2020

1,869 citations recorded by the source corpus.

CRISPR–Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy termed selective organ targeting (SORT) wherein multiple classes of lipid nanoparticles are systematically engineered to exclusively edit extrahepatic tissues via addition of a supplemental SORT molecule. Lung-, spleen- and liver-targeted SORT lipid nanoparticles were designed to selectively edit therapeutically relevant cell types including epithelial cells, endothelial cells, B cells, T cells and hepatocytes. SORT is compatible with multiple gene editing techniques, including mRNA, Cas9 mRNA/single guide RNA and Cas9 ribonucleoprotein complexes, and is envisioned to aid the development of protein replacement and gene correction therapeutics in targeted tissues. The addition of selective organ targeting molecules to nanoparticles allows the specific targeting of extrahepatic tissues, enabling gene editing of distinct cell populations outside the liver.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d4464b7450f8bb07db5703a6e82855779ae3bc51

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

  1. J. Kulkarni
  2. Camilla Hald Albertsen
  3. K. Petersson
  4. Marianne Lind
  5. J. Simonsen
  6. D. Witzigmann

Citations in the corpus